Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)

被引：0
|
作者：
Normanno, N. [1 ]
Rachiglio, A. M. [1 ]
Abate, R. Esposito [1 ]
Orlandi, A. [2 ]
Maiello, E. [3 ]
Maglietta, G. [4 ,5 ]
Damato, A. [3 ]
Maiello, M. R. [1 ]
Carotenuto, M. [1 ]
Calegari, M. A. [2 ]
Antonuzzo, L. [6 ]
Bordonaro, R. [7 ]
Zampino, M. G. [8 ]
Tamberi, S.
Lonardi, S. [9 ]
Avallone, A. [10 ]
Latiano, T. P. [3 ]
Tamburini, E. [11 ]
Barone, C. A. [2 ]
Pinto, C.
机构：
[1] Ist Nazl Tumori IRCCS Fondazione G Pascale, Translat Res Dept, Naples, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Med Oncol Dept, Rome, Italy
[3] Med Oncol, IRCCS Fdn Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
[4] Azienda Osped Univ Parma, Clin & Epidemiol Res Unit, Parma, Italy
[5] IRCCS, Azienda Osped Arcispedale Santa Maria Nuov, Reggio Emilia, Italy
[6] AOUC, Med Oncol Dept, Florence, Italy
[7] Dept Oncol, Azienda Osped ARNAS Garibaldi, Catania, Italy
[8] Osped Santa Maria Croci, Med Oncol, Ravenna, Italy
[9] IRCCS, Dept Oncol, IOV Ist Oncol Veneto, Padua, Italy
[10] IRCCS Fdn G Pascale, Ist Nazl Tumori, Abdominal Oncol Dept, Naples, Italy
[11] Azienda Osped Cardinale Giovanni Panico, Med Oncol, Tricase, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.122
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
111P
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [21] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, S.
    Jung, A.
    Rossius, L.
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Moehler, M.
    Scheithauer, W.
    Kirchner, T.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
  • [22] Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
    Han, Jiaqi
    Xiao, Desheng
    Tan, Chongqing
    Zeng, Xiaohui
    Hu, Huabin
    Zeng, Shan
    Jiang, Qin
    She, Longjiang
    Yao, Linli
    Li, Li
    Tang, Lanhua
    Ma, Jian
    Huang, Jin
    Shen, Liangfang
    CANCER CONTROL, 2020, 27 (01)
  • [23] A COST-EFFECTIVENESS ANALYSIS (CEA) OF CETUXIMAB plus FOLFIRI COMPARED TO BEVACIZUMAB plus FOLFIRI AS FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC): A US ANALYSIS BASED ON LOCATION OF PRIMARY TUMOR
    Evans, R.
    Aggarwal, H.
    Takundwa, R.
    Chin, S.
    Fenwick, E.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [24] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Ciuleanu, T. E.
    Kurteva, G.
    Ocvirk, J.
    Beslija, S.
    Koza, I.
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Scheithauer, W.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
    Price, Timothy
    Shen, Lin
    Ma, Brigette
    Esser, Regina
    Chen, Wenfeng
    Gibbs, Peter
    Lim, Robert
    Cheng, Ann-Lii
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (04) : 225 - 230
  • [27] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
  • [28] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [29] ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) plus BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
    Torrecillas, L.
    Vargas, J.
    VALUE IN HEALTH, 2008, 11 (06) : A469 - A470
  • [30] Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
    De Stefano, A.
    Nasti, G.
    Febbraro, A.
    Rosati, G.
    Giuliani, F.
    Santini, D.
    Aprile, G.
    Scartozzi, M.
    Silvestris, F.
    Luppi, G.
    Lolli, I.
    Mastroianni, C.
    Leo, S.
    Montesarchio, V.
    Gridelli, C.
    Pozzo, C.
    Sperti, E.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345